Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2000

View Archived Issues

Ciba Vision and QLT expand strategic alliance for developing new treatments for eye diseases

Recordati acquires the French pharmaceutical company Bouchara

FDA reviews Thymoglobulin IND for evaluation in MDS patients

DSRB review supports continuation of Allovectin-7 trials

Mechanism of action of OvaRex clarified

IND filed for DAT imaging agent in PD and ADHD

Forest and Warner-Lambert terminate Celexa copromotion agreement

Concerta to be copromoted by Alza and McNeil for ADD/ADHD

Olanzapine salts with improved pharmaceutical properties

Potent CETP inhibitors in the Pharmacia pipeline

Compounds and methods for treating atherosclerosis and other coronary artery diseases

Novel Taisho compounds enhance osteoblast differentiation

Lambda synthesizes photosensitizers with enhanced activity compared to Photofrin

New isosorbide mononitrate derivatives with reduced tolerance under study at Lacer

Therapeutically active bicyclic compounds for herpesvirus infections

Immunogenic chemokine receptor peptides prepared at Corixa for use in autoimmune diseases

BNP-7787 to enter phase III clinical trials as chemoprotectant

Pfizer/Warner-Lambert merger appears imminent

Tiotropium bromide produces long-lasting bronchodilatation in patients with COPD

Potential new gastric prokinetic agent related to human motilin

Xenova updates clinical progress during Q1 2000

R&D on aminoacyl-tRNA synthetase inhibitors continues at SB; two new compounds identified

PCO prodrugs with slow onset and long duration of action presented by Daiichi

DB-289 development on track --Immtech to file IND in July

Free radical scavenger T-0162 protects against ischemia/reperfusion myocardial injury

New treatments for ALL in active development at major research institute

Small phase II study of Xerecept in peritumoral brain edema yields encouraging results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...